## WAT: Waters Corporation - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -2.5% below STRENGTH zone (3.0-6.0%); PEG 6.29 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-3.0% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($375.77)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 3, Bearish: 0)

**1. Jim Cramer on Waters Corporation: "I Think It Should Be Loved on Wall Street**
- Source: Finviz | 20251204T120500 | Bullish | Relevance: 100%
- Jim Cramer discussed Waters Corporation (NYSE: WAT), highlighting its upcoming merger with Becton, Dickinson's biosciences and diagnostics business. Despite an initial negative market reaction to the merger announcement in July, the stock has rebounded significantly, up 45% from its August lows, following a strong earnings report. Cramer believes that once the merger closes in Q1 next year, Waters will become a much bigger player that "should be loved on Wall Street."

**2. Breath Diagnostics completes install of advanced mass spectrometry system**
- Source: Mugglehead Magazine | 20251204T073730 | Bullish | Relevance: 100%
- Breath Diagnostics has successfully installed and made operational a new Xevo TQ Absolute XR Triple Quadrupole Mass Spectrometer from Waters Corp (NYSE: WAT). This advanced system significantly boosts performance and energy efficiency for detecting biomarkers related to lung diseases, enhancing sensitivity and stability crucial for breath diagnostics. The installation marks a step towards scalable, non-invasive early detection of lung cancer and other diseases.

**3. Waters Corporation (NYSE:WAT) Given Average Rating of "Moderate Buy" by Brokerages**
- Source: MarketBeat | 20251204T060856 | Somewhat-Bullish | Relevance: 100%
- Waters Corporation (NYSE:WAT) has received a consensus "Moderate Buy" rating from eighteen brokerages, with an average 1-year price target of $384.33 among reporting firms. Institutional investors hold a significant 94.01% of the stock, and several firms have recently increased their stakes. Waters reported $2.29 EPS last quarter, with analysts forecasting $12.86 EPS for the current year.

**4. Morgan Stanley initiates Waters Corp stock coverage with Equalweight rating**
- Source: Investing.com | 20251202T101700 | Neutral | Relevance: 100%
- Morgan Stanley initiated coverage on Waters Corp. (NYSE:WAT) with an Equalweight rating and a price target of $423.00, citing the company's strong financial performance and recurring business model. Despite its operational strengths and growth in new segments, concerns were raised regarding the acquisition of Becton Dickinsonâ€™s Biosciences and Diagnostics businesses, which could introduce "nearer-term uncertainty" and integration challenges. The investment bank noted that while the standalone business is favorable, these challenges could limit near-term visibility, aligning with analyst revisions and a high P/E ratio for Waters.

**5. Why Is Waters (WAT) Up 6.9% Since Last Earnings Report?**
- Source: Yahoo Finance | 20251204T103000 | Bullish | Relevance: 100%
- Waters (WAT) shares have increased by 6.9% since its last earnings report, outperforming the S&P 500. The company reported strong Q3 2025 results, with non-GAAP earnings beating estimates by 5.92% and net sales increasing 8% year over year. Waters also raised its 2025 guidance, projecting continued sales and earnings growth.

### Analyst Activity

**Target Signal:** VERY_BULLISH (Raises: 2, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-02 | Morgan Stanley | $423 | $0 | 0% |
| 2025-11-05 | TD Cowen | $390 | $345 | +13% |
| 2025-11-05 | Wells Fargo | $385 | $315 | +22% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-02 | Morgan Stanley | init | Equal-Weight |
| 2025-11-05 | TD Cowen | main | Hold |
| 2025-11-05 | Wells Fargo | main | Equal-Weight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 2 ($0.00M) |
| Sells | 1 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 52.2% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 8 / 2 |

**Top Holders:**
- Vanguard Group Inc: 12.9% (+3.3%)
- Blackrock Inc.: 10.2% (-7.6%)
- Fundsmith LLP: 6.6% (+9.6%)
- Massachusetts Financ: 4.5% (+44.3%)
- State Street Corpora: 4.5% (+0.1%)

### Key Risks

1. Momentum deterioration: MRS_10 falling (-3.0% 5d) with bearish MACD, trend may be turning.
2. Valuation stretched: PEG 6.3x requires aggressive growth execution.
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 6.29 signals overvaluation risk, limited margin of safety. Forward P/E 27.7x stretched relative to 9% growth. Quality metrics strong (ROE 33%, ROA 12%, margin 21%). Analyst sentiment positive (2 raises, avg +18%). Institutional flow bullish (8 buying vs 2 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $23.0B |
| Beta | 1.16 |
| 52W Range | $275.05 - $423.56 |
| Short Interest | 5.0% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 6.29 |
| Forward P/E | 27.7 |
| Current P/E | 30.2 |
| YoY Growth | 9.0% |
| EPS Direction | STABLE |

### Technicals

MRS_10 deteriorating from 0.6% to -2.5% (-3.0% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 5.5pp (needs >3.0% for momentum thesis). Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram bearish (-1.11), momentum weakening. OFD pattern: -DLN (Support test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -2.50% (CS: 26) | Weak |
| RSI_14 | 63.8 | Neutral |
| MACD Histogram | -1.11 | Bearish |
| vs SMA20 | 1.021x | Above |
| vs SMA50 | 1.114x | Above |
| vs SMA200 | 1.170x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $396.37
- **Stop Loss:** $375.77 (5.2% risk)
- **Target:** $416.97 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 24
- **Position Value:** $9,512.88
- **Portfolio %:** 9.51%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

*NORMAL regime with moderate risk appetite and mixed signals. VIX at 15.78 indicates calm conditions but breadth at 53% suggests narrow participation. Fed policy remains neutral with 42 days to next meeting, supporting steady positioning with sector selectivity.*

### Earnings

**Next:** 2026-02-11 (Est: $4.51)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $3.22 | $3.40 | +5.5% |
| 2025Q2 | $2.94 | $2.95 | +0.3% |
| 2025Q1 | $2.22 | $2.25 | +1.2% |
| 2024Q4 | $4.03 | $4.10 | +1.7% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*